Gunnar Kristensen
Overview
Explore the profile of Gunnar Kristensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feroz B, Pan T, Leitner K, Ebner C, Steger K, Kildal W, et al.
Int J Gynecol Cancer
. 2024 Jul;
34(11):1711-1718.
PMID: 38969503
Objective: Immune checkpoint inhibitors have recently demonstrated benefit in patients with advanced and recurrent endometrial carcinoma. This retrospective study investigated immune checkpoint molecules in endometrial carcinoma as they pertain to...
2.
Grisham R, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza M, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4068-4075.
PMID: 37581616
Purpose: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). Patients And Methods: Mutation/copy-number analysis was performed on tissue obtained pre-randomization....
3.
Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, et al.
J Clin Oncol
. 2022 Nov;
41(4):893-902.
PMID: 36332161
Purpose: To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer. Methods: In this multicenter, open-label, randomized...
4.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al.
N Engl J Med
. 2021 Dec;
385(23):2123-2131.
PMID: 34874631
Background: Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods: We randomly assigned patients with recurrent...
5.
Monk B, Grisham R, Banerjee S, Kalbacher E, Mirza M, Romero I, et al.
J Clin Oncol
. 2020 Aug;
38(32):3753-3762.
PMID: 32822286
Purpose: Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study...
6.
Norell C, Butler J, Farrell R, Altman A, Bentley J, Cabasag C, et al.
Int J Gynecol Cancer
. 2020 Aug;
30(11):1748-1756.
PMID: 32784203
Introduction: The International Cancer Benchmarking Partnership demonstrated international differences in ovarian cancer survival, particularly for women aged 65-74 with advanced disease. These findings suggest differences in treatment could be contributing...
7.
Paoletti X, Lewsley L, Daniele G, Cook A, Yanaihara N, Tinker A, et al.
JAMA Netw Open
. 2020 Jan;
3(1):e1918939.
PMID: 31922558
Importance: The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian cancer. Evidence is lacking...
8.
Gonzalez Martin A, Oza A, Embleton A, Pfisterer J, Ledermann J, Pujade-Lauraine E, et al.
Gynecol Oncol
. 2018 Nov;
152(1):53-60.
PMID: 30449719
Objective: In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS;...
9.
Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K
Int J Gynecol Cancer
. 2018 Oct;
28(9):1789-1795.
PMID: 30365455
Objectives: Adjuvant treatment of high-risk endometrial cancer (EC) is still controversial. Several studies have tried to clarify the best treatment strategy, and guidelines have been made, but no study to...
10.
Halvorsen A, Kristensen G, Embleton A, Adusei C, Barretina-Ginesta M, Beale P, et al.
Dis Markers
. 2017 Mar;
2017:3098542.
PMID: 28293063
Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify microRNAs in plasma for predicting response to treatment and outcome. We have investigated microRNAs in plasma from...